Analysis of the storage and secretion of von willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease

Blood

Volumn 121, Issue 14, 2013, Pages 2762-2772

  Wang, Jiong Wei ^a,b   Bouwens, Eveline A M ^c,d   Pintao, Maria Carolina ^a   Voorberg, Jan ^c,e   Safdar, Huma ^a   Valentijn, Karine M ^a   De Boer, Hetty C ^a   Mertens, Koen ^c,d   Reitsma, Pieter H ^a   Eikenboom, Jeroen ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; PADGEM PROTEIN; PRO VON WILLEBRAND FACTOR; UNCLASSIFIED DRUG; VASOPRESSIN V2 RECEPTOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR PROPEPTIDE;

ARTICLE; BLOOD CELL; BLOOD OUTGROWTH ENDOTHELIAL CELL; CELL ISOLATION; CELL MEMBRANE; CELL SURFACE; CLINICAL ARTICLE; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; EXOCYTOSIS; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VON WILLEBRAND DISEASE; WEIBEL PALADE BODY; CELL CULTURE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; GENOTYPE; MALE; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

CELLS, CULTURED; ENDOPLASMIC RETICULUM; ENDOTHELIAL CELLS; EXOCYTOSIS; FEMALE; FLOW CYTOMETRY; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MUTATION, MISSENSE; PHENOTYPE; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND FACTOR; WEIBEL-PALADE BODIES;

MLCS; MLOWN;

EID: 84878228265     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-434373     Document Type: Article

References (43)

1. Sadler JE, Budde U, Eikenboom JC, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
2. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood. 2011;117(19):5033-5043.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67: 395-424.
4. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
5. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.
6. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100(12):4033-4039.
7. Wang JW, Eikenboom J. Von Willebrand disease and Weibel-Palade bodies. Hamostaseologie. 2010;30(3):150-155.
8. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost. 2009;7(Suppl 1): 65-70.
9. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123-134.
10. Hannah MJ, Williams R, Kaur J, Hewlett LJ, Cutler DF. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol. 2002;13(4):313-324.
11. Wang JW, Valentijn KM, de Boer HC, et al. Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease. J Biol Chem. 2011;286(27): 24180-24188.
12. Michaux G, Hewlett LJ, Messenger SL, Goodeve AC, Peake IR, Daly ME, Cutler DF. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003;102(7):2452-2458.
13. Haberichter SL, Allmann AM, Jozwiak MA, Montgomery RR, Gill JC. Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage. J Thromb Haemost. 2009;7(4):641-650.
14. Jeanneau C, Avner P, Sultan Y. Use of monoclonal antibody and colloidal gold in E.M. localization of von Willebrand factor in megakaryocytes and platelets. Cell Biol Int Rep. 1984;8(10):841-848.
15. Haberichter SL, Budde U, Obser T, Schneppenheim S, Wermes C, Schneppenheim R. The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. Blood. 2010; 115(22):4580-4587.
16. Castaman G, Giacomelli SH, Jacobi P, et al. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost. 2010;8(9):2011-2016.
17. Berber E, James PD, Hough C, Lillicrap D. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution. J Thromb Haemost. 2009;7(10):1672-1679.
18. Booyse FM, Quarfoot AJ, Chediak J, Stemerman MB, Maciag T. Characterization and properties of cultured human von Willebrand umbilical vein endothelial cells. Blood. 1981;58(4):788-796.
19. Ewenstein BM, Inbal A, Pober JS, Handin RI. Molecular studies of von Willebrand disease: reduced von Willebrand factor biosynthesis, storage, and release in endothelial cells derived from patients with type I von Willebrand disease. Blood. 1990;75(7):1466-1472.
20. Federici AB, de Groot PG, Moia M, Ijsseldijk MJ, Sixma JJ, Mannucci PM. Type I von Willebrand disease, subtype 'platelet low': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. Br J Haematol. 1993;83(1):88-93.
21. Levene RB, Booyse FM, Chediak J, Zimmerman TS, Livingston DM, Lynch DC. Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease. Proc Natl Acad Sci USA. 1987;84(18): 6550-6554.
22. de Groot PG, Federici AB, de Boer HC, d'Alessio P, Mannucci PM, Sixma JJ. von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets. Proc Natl Acad Sci USA. 1989;86(10):3793-3797.
23. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105(1):71-77.
24. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9): 2752-2760.
25. Bouwens EA, Mourik MJ, van den Biggelaar M, Eikenboom JC, Voorberg J, Valentijn KM, Mertens K. Factor VIII alters tubular organization and functional properties of von Willebrand factor stored in Weibel-Palade bodies. Blood. 2011; 118(22):5947-5956.
26. Romani de Wit T, Rondaij MG, Hordijk PL, Voorberg J, van Mourik JA. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23(5):755-761.
27. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996; 88(8):2951-2958.
28. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost. 2004;2(2): 257-265.
29. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
30. Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762-771.
31. Wagner SJ, Myrup AC. Toward closed-system culture of blood origin endothelial cells. Transfusion. 2005;45(7):1201-1207.
32. Esposito B, Gambara G, Lewis AM, et al. NAADP links histamine H1 receptors to secretion of von Willebrand factor in human endothelial cells. Blood. 2011;117(18):4968-4977.
33. Nossent AY, VAN Marion V, VAN Tilburg NH, Rosendaal FR, Bertina RM, VAN Mourik JA, Eikenboom HC. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost. 2006;4(12): 2556-2562.
34. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost. 1998;80(1):37-41.
35. Wang JW, Valentijn JA, Valentijn KM, Dragt BS, Voorberg J, Reitsma PH, Eikenboom J. Formation of platelet-binding von Willebrand factor strings on non-endothelial cells. J Thromb Haemost. 2012; 10(10):2168-2178.
36. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10): 4979-4985.
37. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressininduced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106(1):107-116.
38. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1(4): 682-689.
39. Bodó I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood. 2001;98(10): 2973-2979.
40. O'Brien LA, Sutherland JJ, Hegadorn C, et al. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. J Thromb Haemost. 2004;2(7): 1135-1142.
41. Allen S, Abuzenadah AM, Blagg JL, et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood. 2000;95(6):2000-2007.
42. Wang JW, Groeneveld DJ, Cosemans G, et al. Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. Haematologica. 2012;97(6): 859-866.
43. Allen S, Goodeve AC, Peake IR, Daly ME. Endoplasmic reticulum retention and prolonged association of a von Willebrand's disease-causing von Willebrand factor variant with ERp57 and calnexin. Biochem Biophys Res Commun. 2001; 280(2):448-453.